Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

Proportion of US Hospitalized Medically Ill Patients Who May Qualify for Extended Thromboprophylaxis.

Miao B, Chalupadi B, Clark B, Descoteaux A, Huang D, Ilham S, Ly B, Spyropoulos AC, Coleman CI.

Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619850897. doi: 10.1177/1076029619850897.

PMID:
31088302
2.

Increased Transfusion Requirements with Pharmacologic Thromboembolism Prophylaxis During Inflammatory Bowel Disease Exacerbation.

Sultan K, Shah D, Bhorania K, Zhou E, Khan S, Kohn N, Qiu M, Spyropoulos A.

Dig Dis Sci. 2019 May 7. doi: 10.1007/s10620-019-05650-2. [Epub ahead of print]

PMID:
31065899
3.

Optimization of Patterned Surfaces for Improved Superhydrophobicity through Cost-Effective Large-Scale Computations.

Krokos V, Pashos G, Spyropoulos AN, Kokkoris G, Papathanasiou AG, Boudouvis AG.

Langmuir. 2019 May 9. doi: 10.1021/acs.langmuir.9b00588. [Epub ahead of print]

PMID:
31033295
4.

Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation.

Peterson ED, Ashton V, Chen YW, Wu B, Spyropoulos AC.

Am Heart J. 2019 Feb 20;212:113-119. doi: 10.1016/j.ahj.2019.02.001. [Epub ahead of print]

5.

Uptake and Utilization of the Management of Anticoagulation in the Periprocedural Period App: Longitudinal Analysis.

Spyropoulos AC, Myrka A, Triller DM, Ragan S, York C, King JM, Lee TK.

JMIR Mhealth Uhealth. 2018 Dec 21;6(12):e11090. doi: 10.2196/11090.

6.

Thromboprophylaxis after Hospitalization for Medical Illness.

Spyropoulos AC, Barnathan ES, Raskob GE; MARINER Investigators.

N Engl J Med. 2018 Dec 6;379(23):2280. doi: 10.1056/NEJMc1813803. No abstract available.

PMID:
30575454
7.

Treatment of Venous Thromboembolism in Elite Athletes: A Suggested Approach to Individualized Anticoagulation.

Nazha B, Pandya B, Spyropoulos AC, Kessler CM.

Semin Thromb Hemost. 2018 Nov;44(8):813-822. doi: 10.1055/s-0038-1673690. Epub 2018 Oct 8. Review.

PMID:
30296792
8.

Erratum to: The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant who Need an Elective Surgery or Procedure: Design and Rationale.

Douketis JD, Spyropoulos AC, Anderson JM, Arnold DM, Bates SM, Blostein M, Carrier M, Caprini JA, Clark NP, Coppens M, Dentali F, Duncan J, Gross PL, Kassis J, Kowalski S, Lee AY, Gal GL, Templier GL, Li N, MacKay E, Shah V, Shivakumar S, Solymoss S, Spencer FA, Syed S, Tafur AJ, Vanassche T, Thiele T, Wu C, Yeo E, Schulman S.

Thromb Haemost. 2018 Sep;118(9):1679-1680. doi: 10.1055/s-0038-1668582. Epub 2018 Sep 14. No abstract available.

PMID:
30216954
9.

Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.

Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE; MARINER Investigators.

N Engl J Med. 2018 Sep 20;379(12):1118-1127. doi: 10.1056/NEJMoa1805090. Epub 2018 Aug 26.

10.

Defining Minimum Necessary Anticoagulation-Related Communication at Discharge: Consensus of the Care Transitions Task Force of the New York State Anticoagulation Coalition.

Triller D, Myrka A, Gassler J, Rudd K, Meek P, Kouides P, Burnett AE, Spyropoulos AC, Ansell J.

Jt Comm J Qual Patient Saf. 2018 Nov;44(11):630-640. doi: 10.1016/j.jcjq.2018.04.015. Epub 2018 Jul 24.

PMID:
30064950
11.

Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.

Nazha B, Pandya B, Cohen J, Zhang M, Lopes RD, Garcia DA, Sherwood MW, Spyropoulos AC.

Circulation. 2018 Oct 2;138(14):1402-1411. doi: 10.1161/CIRCULATIONAHA.117.031457.

PMID:
29794081
12.

Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis.

Kohn CG, Lyman GH, Beyer-Westendorf J, Spyropoulos AC, Bunz TJ, Baker WL, Eriksson D, Meinecke AK, Coleman CI.

J Natl Compr Canc Netw. 2018 May;16(5):491-497. doi: 10.6004/jnccn.2018.7008.

PMID:
29752323
13.

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism.

Coleman CI, Beyer-Westendorf J, Bunz TJ, Mahan CE, Spyropoulos AC.

Clin Appl Thromb Hemost. 2018 May;24(4):575-582. doi: 10.1177/1076029618758955. Epub 2018 Mar 8.

PMID:
29514466
14.

The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale.

Douketis JD, Spyropoulos AC, Anderson JM, Arnold DM, Bates SM, Blostein M, Carrier M, Caprini JA, Clark NP, Coppens M, Dentali F, Duncan J, Gross PL, Kassis J, Kowalski S, Lee AY, Le Gal G, Le Templier G, Li N, MacKay E, Shah V, Shivakumar S, Solymoss S, Spencer FA, Syed S, Tafur AJ, Vanassche T, Thiele T, Wu C, Yeo E, Schulman S.

Thromb Haemost. 2017 Dec;117(12):2415-2424. doi: 10.1160/TH17-08-0553. Epub 2017 Dec 6.

PMID:
29212129
15.

Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.

Mahan CE, Burnett AE, Fletcher ML, Spyropoulos AC.

Hosp Pract (1995). 2018 Feb;46(1):5-15. doi: 10.1080/21548331.2018.1410053. Epub 2017 Nov 30. Review.

PMID:
29171776
16.

Direct oral anticoagulants in the treatment of pulmonary embolism.

Eldredge JB, Spyropoulos AC.

Curr Med Res Opin. 2018 Jan;34(1):131-140. doi: 10.1080/03007995.2017.1364227. Epub 2017 Sep 1. Review.

PMID:
28771049
17.

New paradigms in venous thromboprophylaxis of medically ill patients.

Spyropoulos AC, Raskob GE.

Thromb Haemost. 2017 Aug 30;117(9):1662-1670. doi: 10.1160/TH17-03-0168. Epub 2017 Jun 22.

PMID:
28640324
18.

A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study.

Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El Shemmari S, Larsen AK, Elalamy I; COMPASS–CAT Working Group.

Oncologist. 2017 Oct;22(10):1222-1231. doi: 10.1634/theoncologist.2016-0414. Epub 2017 May 26.

19.

Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated With Different Outcomes Among Patients With Venous Thromboembolism?

Spyropoulos AC, Preblick R, Kwong WJ, Lingohr-Smith M, Lin J.

Clin Appl Thromb Hemost. 2017 Sep;23(6):532-541. doi: 10.1177/1076029616680475. Epub 2016 Nov 30.

PMID:
27899520
20.

To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment.

Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD.

J Thromb Haemost. 2016 Dec;14(12):2556-2559. doi: 10.1111/jth.13505. Epub 2016 Oct 24. No abstract available.

21.

Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed.

Milling TJ Jr, Spyropoulos AC.

Am J Emerg Med. 2016 Nov;34(11S):19-25. doi: 10.1016/j.ajem.2016.09.049. Epub 2016 Sep 28. Review.

22.

A multiple sclerosis-like disorder in patients with OPA1 mutations.

Yu-Wai-Man P, Spyropoulos A, Duncan HJ, Guadagno JV, Chinnery PF.

Ann Clin Transl Neurol. 2016 Jul 19;3(9):723-9. doi: 10.1002/acn3.323. eCollection 2016 Sep.

23.

Perioperative Management of the Direct Oral Anticoagulants: A Case-Based Review.

Bell BR, Spyropoulos AC, Douketis JD.

Hematol Oncol Clin North Am. 2016 Oct;30(5):1073-84. doi: 10.1016/j.hoc.2016.05.005. Review.

PMID:
27637308
24.

Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed.

Milling TJ Jr, Spyropoulos AC.

Am J Med. 2016 Nov;129(11S):S54-S63. doi: 10.1016/j.amjmed.2016.06.006. Epub 2016 Aug 26. Review.

25.

Cost-of-illness model for venous thromboembolism.

Mahan CE, Barco S, Spyropoulos AC.

Thromb Res. 2016 Sep;145:130-2. doi: 10.1016/j.thromres.2016.06.022. Epub 2016 Jun 23. No abstract available.

PMID:
27354154
26.

Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation.

Kittelson JM, Steg PG, Halperin JL, Goldenberg NA, Schulman S, Spyropoulos AC, Kessler CM, Turpie AG, Cutler NR, Hiatt WR; Antithrombotic Trials Leadership and Steering (ATLAS) Group.

Thromb Haemost. 2016 Aug 30;116(3):544-53. doi: 10.1160/TH15-12-1000. Epub 2016 Jun 23.

PMID:
27346176
27.

External validation of the IMPROVE Bleeding Risk Assessment Model in medical patients.

Rosenberg DJ, Press A, Fishbein J, Lesser M, McCullagh L, McGinn T, Spyropoulos AC.

Thromb Haemost. 2016 Aug 30;116(3):530-6. doi: 10.1160/TH16-01-0003. Epub 2016 Jun 16.

PMID:
27307054
28.

North American Thrombosis Forum, AF Action Initiative Consensus Document.

Ruff CT, Ansell JE, Becker RC, Benjamin EJ, Deicicchi DJ, Mark Estes NA, Ezekowitz MD, Fanikos J, Fareed J, Garcia D, Giugliano RP, Goldhaber SZ, Granger C, Healey JS, Hull R, Hylek EM, Libby P, Lopes RD, Mahaffey KW, Mega J, Piazza G, Sasahara AA, Sorond FA, Spyropoulos AC, Walenga JM, Weitz JI.

Am J Med. 2016 May;129(5 Suppl):S1-S29. doi: 10.1016/j.amjmed.2016.02.001.

PMID:
27126598
29.

Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation.

Grottke O, Aisenberg J, Bernstein R, Goldstein P, Huisman MV, Jamieson DG, Levy JH, Pollack CV Jr, Spyropoulos AC, Steiner T, Del Zoppo GJ, Eikelboom J.

Crit Care. 2016 Apr 28;20(1):115. doi: 10.1186/s13054-016-1275-8. Review.

30.

Validation of Risk Assessment Models of Venous Thromboembolism in Hospitalized Medical Patients.

Greene MT, Spyropoulos AC, Chopra V, Grant PJ, Kaatz S, Bernstein SJ, Flanders SA.

Am J Med. 2016 Sep;129(9):1001.e9-1001.e18. doi: 10.1016/j.amjmed.2016.03.031. Epub 2016 Apr 21.

PMID:
27107925
31.

Venous thromboembolism following hematopoietic stem cell transplantation-a systematic review and meta-analysis.

Zahid MF, Murad MH, Litzow MR, Hogan WJ, Patnaik MS, Khorana A, Spyropoulos AC, Hashmi SK.

Ann Hematol. 2016 Sep;95(9):1457-64. doi: 10.1007/s00277-016-2673-3. Epub 2016 Apr 22. Review.

PMID:
27103008
32.

The BRIDGE trial: What the hospitalist should know.

Nazha B, Spyropoulos AC.

J Hosp Med. 2016 Sep;11(9):652-7. doi: 10.1002/jhm.2594. Epub 2016 Apr 21. Review.

PMID:
27098835
33.

Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery.

Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD.

J Thromb Haemost. 2016 May;14(5):875-85. doi: 10.1111/jth.13305. Epub 2016 Apr 7. Review.

34.

Looking to the past provides inspiration for the future.

Spyropoulos A.

Nurs Stand. 2016 Jan 27;30(22):33. doi: 10.7748/ns.30.22.33.s40. No abstract available.

PMID:
26967879
35.

Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial.

Douketis JD, Healey JS, Brueckmann M, Fraessdorf M, Spyropoulos AC, Wallentin L, Oldgren J, Reilly P, Ezekowitz MD, Connolly SJ, Yusuf S, Eikelboom JW.

Thromb Res. 2016 Mar;139:77-81. doi: 10.1016/j.thromres.2016.01.004. Epub 2016 Jan 9.

PMID:
26916299
36.

The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.

Raskob GE, Spyropoulos AC, Zrubek J, Ageno W, Albers G, Elliott CG, Halperin J, Haskell L, Hiatt WR, Maynard GA, Peters G, Spiro T, Steg PG, Suh EY, Weitz JI.

Thromb Haemost. 2016 Jun 2;115(6):1240-8. doi: 10.1160/TH15-09-0756. Epub 2016 Feb 4.

37.

Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH.

Kaatz S, Ahmad D, Spyropoulos AC, Schulman S; Subcommittee on Control of Anticoagulation.

J Thromb Haemost. 2015 Nov;13(11):2119-26. No abstract available.

PMID:
26764429
38.

European Union-28: An annualised cost-of-illness model for venous thromboembolism.

Barco S, Woersching AL, Spyropoulos AC, Piovella F, Mahan CE.

Thromb Haemost. 2016 Apr;115(4):800-8. doi: 10.1160/TH15-08-0670. Epub 2015 Nov 26.

PMID:
26607486
39.

All-cause mortality and use of antithrombotics within 90 days of discharge in acutely ill medical patients.

Mahan CE, Fields LE, Mills RM, Stephenson JJ, Fu AC, Fisher MD, Spyropoulos AC.

Thromb Haemost. 2015 Oct;114(4):685-94. doi: 10.1160/TH15-02-0108. Epub 2015 Jul 23.

PMID:
26202514
40.

Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings.

Goldenberg NA, Abshire T, Blatchford PJ, Fenton LZ, Halperin JL, Hiatt WR, Kessler CM, Kittelson JM, Manco-Johnson MJ, Spyropoulos AC, Steg PG, Stence NV, Turpie AG, Schulman S; Kids-DOTT Trial Investigators.

J Thromb Haemost. 2015 Sep;13(9):1597-605. doi: 10.1111/jth.13038. Epub 2015 Aug 11.

41.

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.

Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, Garcia DA, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AG, Hasselblad V, Ortel TL; BRIDGE Investigators.

N Engl J Med. 2015 Aug 27;373(9):823-33. doi: 10.1056/NEJMoa1501035. Epub 2015 Jun 22.

42.

Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.

Francis CW, Kessler CM, Goldhaber SZ, Kovacs MJ, Monreal M, Huisman MV, Bergqvist D, Turpie AG, Ortel TL, Spyropoulos AC, Pabinger I, Kakkar AK.

J Thromb Haemost. 2015 Jun;13(6):1028-35. doi: 10.1111/jth.12923. Epub 2015 May 10.

43.

Direct oral anticoagulants: new drugs and new concepts.

Levy JH, Spyropoulos AC, Samama CM, Douketis J.

JACC Cardiovasc Interv. 2014 Dec;7(12):1333-51. doi: 10.1016/j.jcin.2014.06.014. Review.

44.

Management of anticoagulants in the periprocedural period for patients with cancer.

Pudusseri A, Spyropoulos AC.

J Natl Compr Canc Netw. 2014 Dec;12(12):1713-20. Review.

PMID:
25505212
45.

Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial.

Douketis JD, Healey JS, Brueckmann M, Eikelboom JW, Ezekowitz MD, Fraessdorf M, Noack H, Oldgren J, Reilly P, Spyropoulos AC, Wallentin L, Connolly SJ.

Thromb Haemost. 2015 Mar;113(3):625-32. doi: 10.1160/TH14-04-0305. Epub 2014 Dec 4.

PMID:
25472710
46.

External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system.

Rosenberg D, Eichorn A, Alarcon M, McCullagh L, McGinn T, Spyropoulos AC.

J Am Heart Assoc. 2014 Nov 17;3(6):e001152. doi: 10.1161/JAHA.114.001152.

47.

Features of electronic health records necessary for the delivery of optimized anticoagulant therapy: consensus of the EHR Task Force of the New York State Anticoagulation Coalition.

Spyropoulos AC, Viscusi A, Singhal N, Gilleylen J, Kouides P, Howard M, Rudd K, Ansell J, Triller DM.

Ann Pharmacother. 2015 Jan;49(1):113-24. doi: 10.1177/1060028014555176. Epub 2014 Oct 16.

PMID:
25325906
48.

Efficacy and safety of early parenteral anticoagulation as a bridge to warfarin after mechanical valve replacement.

Mathew JG, Spyropoulos AC, Yusuf A, Vincent J, Eikelboom J, Shestakovska O, Fremes S, Noora J, Guo L, Peterson M, Pai M, Whitlock R.

Thromb Haemost. 2014 Dec;112(6):1120-8. doi: 10.1160/TH14-03-0284. Epub 2014 Aug 28.

PMID:
25183209
49.

Treatment and long-term management of venous thromboembolism.

Al-Badri A, Spyropoulos AC.

Clin Lab Med. 2014 Sep;34(3):519-36. doi: 10.1016/j.cll.2014.06.011. Epub 2014 Jul 21. Review.

PMID:
25168940
50.

The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism.

Akwaa F, Spyropoulos AC.

Curr Med Res Opin. 2014 Nov;30(11):2179-90. doi: 10.1185/03007995.2014.951425. Epub 2014 Aug 19. Review.

PMID:
25105309

Supplemental Content

Loading ...
Support Center